An in-depth article in GenomeWeb highlights Sutter Health’s work with Canexia to assess if a “triaged, in-house testing strategy improves outcomes, lowers cost, and reduces access inequities.” 

“While most organizations are still outsourcing NGS testing, health institutions are increasingly implementing local testing strategies. In a 2019 precision oncology survey of oncologists and pathologists conducted by Novartis, 83 percent said their organizations send out NGS testing to third-party labs. However, there was a 58 percent increase from 2018 to 2019 in respondents reporting they had in-house NGS testing. Faster turnaround time and better management of patients’ data were among the top advantages cited for in-house NGS testing.”

“An internal testing strategy can also help improve access to clinical trials, which are a big part of precision oncology programs but tend not to be broadly accessible within community practices where most patients get treated. With in-house testing, the institution maintains and manages patients’ samples, which also bolsters an institution’s ability to do research using patients’ biomarker data.” 

“For both Canexia and Sutter, there is also a health equity element to all this. Studies continue to show that despite greater availability of FDA-approved precision oncology treatments in recent years and exponential growth within the genetic testing industry, not all cancer patients are benefitting from these advances.”

Back

Recent Resources

Blog

August 30, 2022

CGC 2022 Key Takeaways

NGS Reporting, Whole Genome Sequencing, and In-House Testing major themes in this year’s meeting